Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer
Biogen has appointed Daniel Quirk, MD as Chief Medical Officer and Head of Medical Affairs, effective October 28, 2024. Dr. Quirk will report to Priya Singhal, Head of Development. Previously, he served as Senior Vice President of Worldwide Medical Affairs for Immunology and Neuroscience at Bristol-Myers Squibb, and held leadership positions at Pfizer. Dr. Quirk's background includes medical practice as Associate Chief of Gastroenterology at Thomas Jefferson University Health Systems, with degrees from Brown University (MD), Harvard School of Public Health (MPH), and Wharton School (MBA).
Biogen ha nominato Daniel Quirk, MD come Chief Medical Officer e Responsabile delle Questioni Mediche, con effetto dal 28 ottobre 2024. Il Dr. Quirk riporterà a Priya Singhal, Responsabile dello Sviluppo. In precedenza, ha ricoperto il ruolo di Vicepresidente Senior degli Affari Medici Globali per l'Immunologia e le Neuroscienze presso Bristol-Myers Squibb, e ha occupato posizioni di leadership in Pfizer. Il background del Dr. Quirk include un'esperienza medica come Vice Capo del Gastroenterologia presso i Thomas Jefferson University Health Systems, con lauree conseguite alla Brown University (MD), alla Harvard School of Public Health (MPH) e alla Wharton School (MBA).
Biogen ha nombrado a Daniel Quirk, MD como Director Médico y Jefe de Asuntos Médicos, efectivo a partir del 28 de octubre de 2024. El Dr. Quirk reportará a Priya Singhal, Jefa de Desarrollo. Anteriormente, se desempeñó como Vicepresidente Senior de Asuntos Médicos a Nivel Mundial para Inmunología y Neurociencia en Bristol-Myers Squibb y ocupó puestos de liderazgo en Pfizer. El Dr. Quirk tiene antecedentes en la práctica médica como Jefe Asociado de Gastroenterología en los Sistemas de Salud de la Universidad Thomas Jefferson, con títulos de la Universidad de Brown (MD), la Escuela de Salud Pública de Harvard (MPH) y la Escuela Wharton (MBA).
Biogen은 Daniel Quirk, MD를 최고 의학 책임자이자 의학 업무 부서장으로 임명하며, 2024년 10월 28일부터 효력을 발휘합니다. Quirk 박사는 개발 책임자인 Priya Singhal에게 보고할 것입니다. 이전에는 Bristol-Myers Squibb의 면역학 및 신경과학 분야에서 세계 의학 업무 수석 부사장직을 역임했으며, Pfizer에서 여러 리더십 직책을 맡았습니다. Quirk 박사의 배경에는 토마스 제퍼슨 대학교 건강 시스템의 위장병학 부서 부장을 역임한 의료 실무가로서의 경력이 포함되며, 브라운 대학교(의학 박사), 하버드 공공 보건 대학원(공중 보건 석사), 워튼 스쿨(MBA)에서 학위를 취득했습니다.
Biogen a nommé Daniel Quirk, MD en tant que médecin-chef et responsable des affaires médicales, avec effet au 28 octobre 2024. Le Dr Quirk rapportera à Priya Singhal, responsable du développement. Auparavant, il était vice-président senior des affaires médicales mondiales pour l'immunologie et les neurosciences chez Bristol-Myers Squibb et a occupé des postes de direction chez Pfizer. Le parcours du Dr Quirk inclut une pratique médicale en tant que médecin-chef adjoint en gastroentérologie au Thomas Jefferson University Health Systems, avec des diplômes de l'université Brown (MD), de la Harvard School of Public Health (MPH) et de la Wharton School (MBA).
Biogen hat Daniel Quirk, MD zum Chief Medical Officer und Leiter der Medizinischen Angelegenheiten ernannt, mit Wirkung zum 28. Oktober 2024. Dr. Quirk wird an Priya Singhal berichten, die Leiterin der Entwicklung ist. Zuvor war er Senior Vice President für weltweite medizinische Angelegenheiten in den Bereichen Immunologie und Neurowissenschaften bei Bristol-Myers Squibb und hatte Führungspositionen bei Pfizer inne. Dr. Quirks Hintergrund umfasst medizinische Tätigkeit als stellvertretender Leiter der Gastroenterologie an den Thomas Jefferson University Health Systems, mit Abschlüssen von der Brown University (MD), der Harvard School of Public Health (MPH) und der Wharton School (MBA).
- Appointment brings extensive medical affairs experience in immunology and neuroscience
- Strong academic and clinical background with prestigious institutions
- Expertise aligns with Biogen's expansion into neurology, immunology, and rare diseases
- None.
CAMBRIDGE, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has appointed Daniel Quirk, M.D., M.P.H., M.B.A. as Chief Medical Officer and Head of Medical Affairs, effective October 28, 2024. Dr. Quirk will report to Priya Singhal, M.D., M.P.H., Head of Development at Biogen.
“At Biogen, scientific and medical leadership is the foundation for everything we do, and this is why we believe Dan will be a perfect fit to lead our Medical Affairs organization going forward,” said Priya Singhal, M.D., M.P.H., Head of Development at Biogen. “With his diverse background in medicine, public health, and business administration, and his extensive experience in medical affairs across both US and global markets, Dan is well-positioned to help drive our leadership forward as we expand further into neurology, immunology, and rare diseases.”
Prior to joining the Biogen team, Dr. Quirk was Senior Vice President of Worldwide Medical Affairs for Immunology and Neuroscience at Bristol-Myers Squibb (BMS), and previously served as Senior Vice President of US Medical Affairs and Vice President of US Medical Affairs for Immunology and Fibrosis at BMS. Earlier in his career, Dr. Quirk held several key leadership positions at Pfizer, with the most recent being Vice President and Medical Category Lead for Inflammation and Immunology in Emerging Markets.
Dan enjoyed a successful medical career before joining industry and served as the Associate Chief of Gastroenterology at Thomas Jefferson University Health Systems in Philadelphia, where he contributed significantly to patient care, clinical research, and medical education.
Dr. Quirk earned his M.D. from Brown University, followed by an M.P.H. from the Harvard School of Public Health and an M.B.A. from The Wharton School at the University of Pennsylvania. Dr. Quirk completed his medical training at the Johns Hopkins Hospital and the Massachusetts General Hospital.
About Biogen
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.
We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media - Facebook, LinkedIn, X, YouTube.
Biogen Safe Harbor
This news release contains forward-looking statements, including regarding the potential of Biogen's commercial business and pipeline programs; the anticipated benefits and potential of investments, and Biogen’s future strategic and financial results. These statements may be identified by words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "may," "plan," "possible," "potential," "will," "would" and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical studies may not be indicative of full results or results from later stage or larger scale clinical studies and do not ensure regulatory approval. You should not place undue reliance on these statements.
These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including without limitation unexpected concerns that may arise from additional data, analysis or results obtained during clinical studies; the occurrence of adverse safety events; risks of unexpected costs or delays; the risk of other unexpected hurdles; regulatory submissions may take longer or be more difficult to complete than expected; regulatory authorities may require additional information or further studies, or may fail or refuse to approve or may delay approval of Biogen's drug candidates; actual timing and content of submissions to and decisions made by the regulatory authorities regarding our products or product candidates; uncertainty of success in the development and potential commercialization of the medicine; failure to protect and enforce Biogen's data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; product liability claims; and third party collaboration risks, results of operations and financial condition. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Biogen's expectations in any forward-looking statement. Investors should consider this cautionary statement as well as the risk factors identified in Biogen's most recent annual or quarterly report and in other reports Biogen has filed with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this news release. Biogen does not undertake any obligation to publicly update any forward-looking statements.
| MEDIA CONTACT: Biogen Jack Cox + 1 781 464 3260 public.affairs@biogen.com | INVESTOR CONTACT: Biogen Stephen Amato +1 781 464 2442 IR@biogen.com |
FAQ
When did Daniel Quirk join Biogen (BIIB) as Chief Medical Officer?
What was Daniel Quirk's previous position before joining Biogen (BIIB)?
What are Dr. Quirk's educational qualifications for his role at Biogen (BIIB)?
Who does the new Biogen (BIIB) Chief Medical Officer report to?
